← All trials
NCT05615727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2024
- First posted
- Nov 14, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 20
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The University of Hong KongLead sponsor
- The University of Hong KongOverall official - principal investigator
- The University of Hong KongReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.